SAT0096 CORRELATION OF GROWTH FACTORS WITH RHEUMATOID ARTHRITIS CLINICAL COURSE INDICATORS

Background The evaluation of early destruction markers in rheumatoid arthritis (RA) is of significant clinical importance for improving the patient`s life quality. One of the immunological markers of RA early diagnosis and of severe disease is antibodies to cyclic citrullinated peptide (ACCP). Instrumental methods for early diagnosis of RA include the ultrasound of joints. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) can stimulate the processes of angiogenesis and proliferation, which in turn can increase the infiltration and hyperplasia of synovia, the growth of pannus mass and contribute to the development of bone and cartilage erosions. Objectives: to establish the correlation of growth factor indicators with markers of the destructive course of rheumatoid arthritis. Methods 194 patients with a diagnosis of RA were examined, among the examined patients women prevailed - 86.6%, the age was 47.7 ± 10.22 years. Positive by the presence of ACCP (> 20 U/ml) was 76.8%, and negative - 23.2%. The ELISA in the serum was determined by the concentration of CRP and TNF-α (Vector-Best, Russia), antibodies to cyclic citrulinated peptide (ACCP) (Euroimmun, Germany), VEGF and FGF (BCM Diagnostic, Canada). Ultrasound of the joints was performed by the device “ESAOTE MyLAB40” (Netherlands, 2011) with a linear sensor of 7.5 L 70 (frequency 7.5 MHz), semi-quantitative evaluation of indicators was used: effusion into the joint space (JS), synovial thickness, vascularization of the synovial membrane (SM), the presence of pannus and bone-cartilage erosion. Results Direct correlations with CRP and ACCP levels (p = 0.02; p = 0.01, respectively), TNFα and DAS28 (p Direct correlations with Ro stage (p Conclusion According to the correlations of VEGF, FGF levels with CRP, ACCP, assessment of synovial vascularization and bone-cartilage erosions - the high levels of VEGF, FGF in the blood can be used as markers of severe destructive course of RA and of the high rate of disease progression, which requires the early aggressive basic therapy of RA with the use of genetically engineered biologic drugs prescription. Disclosure of Interests None declared